Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFT505 in non-alcoholic steatohepatitis
NL-OMON39848Phase 2Active, not recruiting
- Sponsor
- Genfit
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Genfit. Started Mar 2013; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON39848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39848.